Drug Profile
Research programme: Huntington's disease therapeutics - Myometrics
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Myometrics
- Class Antidementias
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Huntington's disease
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Huntington's-disease in United Kingdom
- 01 Aug 2016 Early research in Huntington's disease in United Kingdom (unspecified route)